RxDoctor Payments Data

Yogindra Balhara, MD

Internal Medicine · Chambersburg, PANPI 1134120835

Payments from drug & device makers

$1,127in general payments, 2019–2025

Across 74 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$411
  • GSK$132
  • Sunovion Pharmaceuticals Inc.$93
  • E.r. Squibb & Sons, L.L.C.$72
  • Pfizer$72
  • Astellas Pharma US Inc$53
  • plus $295 from 16 others

What the payments were for

  • Food & beverage$1,127100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,127 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$204,669
Medicare patients
400
Services billed
2,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban687$290,525
MounjaroTirzepatide142$142,425
JanuviaSitagliptin Phosphate123$100,981
XareltoRivaroxaban186$86,056
JardianceEmpagliflozin105$80,751
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$54,935
OzempicSemaglutide50$50,004
XifaxanRifaximin20$46,001
AptiomEslicarbazepine Acetate24$30,085
MyrbetriqMirabegron93$27,263
Breo ElliptaFluticasone/Vilanterol59$24,813
LinzessLinaclotide33$22,569
FarxigaDapagliflozin Propanediol71$21,039
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr34$17,521
TradjentaLinagliptin76$16,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$290,525687 claims
Lilly USA, LLCMounjaro, Trulicity$21$157,888158 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$132$97,269185 claims
Johnson & JohnsonXarelto, Invokana$12$92,045197 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$15$46,00120 claims
AbbVieLinzess, Restasis, Lumigan, Creon$411$44,86088 claims
AstraZenecaFarxiga, Brilinta$11$31,93485 claims
Sunovion Pharmaceuticals Inc.Aptiom$93$30,08524 claims
Astellas Pharma US IncMyrbetriq$53$27,26393 claims
NovartisEntresto$27$7,38316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →